Promatix is an ALSA Group company using multi-omic insights to develop the next generation of cancer therapeutics
Employees: 11-50
Founded date: 2020
Investors 1
| Date | Name | Website |
| - | ALSA Ventu... | alsaventur... |
Mentions in press and media 3
| Date | Title | Description |
| 24.02.2026 | Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity | London and Cambridge, UK — 24 February 2026 — Promatix Biosciences Ltd (Promatix), an emerging UK-based biotechnology company developing innovative new classes of cancer therapies using cis-bispecific antibodies, today presented positive pr... |
| 19.10.2022 | Promatix and Jasmin Fisher Lab at University College London Accelerate Hunt for Oncology Therapeutics with New Algorithms for CipherPro. | London, 19 October 2022 – Promatix, a London-based oncology drug discovery and development company that uses multi-omics to identify novel therapeutics, today announced a collaboration with the laboratory of Professor Jasmin Fisher to devel... |
| 08.03.2021 | ALSA Ventures today announced the launch of Promatix Inc., a Delaware incorporated company, to develop novel therapeutics with the potential to transform the treatment of cancer | London, 8 March 2021 – ALSA Ventures today announced the launch of Promatix Inc., a Delaware incorporated company, to develop novel therapeutics with the potential to transform the treatment of cancer. Promatix will use its multi-omic propr... |